HK1220697A1 - 肽組合物 - Google Patents

肽組合物

Info

Publication number
HK1220697A1
HK1220697A1 HK16108645.4A HK16108645A HK1220697A1 HK 1220697 A1 HK1220697 A1 HK 1220697A1 HK 16108645 A HK16108645 A HK 16108645A HK 1220697 A1 HK1220697 A1 HK 1220697A1
Authority
HK
Hong Kong
Prior art keywords
peptide compositions
peptide
compositions
Prior art date
Application number
HK16108645.4A
Other languages
English (en)
Inventor
Shubh Sharma
Der Ploeg Leonardus H T Van
Bart Henderson
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of HK1220697A1 publication Critical patent/HK1220697A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK16108645.4A 2013-03-15 2016-07-20 肽組合物 HK1220697A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790469P 2013-03-15 2013-03-15
PCT/US2014/028590 WO2014144260A1 (en) 2013-03-15 2014-03-14 Peptide compositions

Publications (1)

Publication Number Publication Date
HK1220697A1 true HK1220697A1 (zh) 2017-05-12

Family

ID=50588892

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108645.4A HK1220697A1 (zh) 2013-03-15 2016-07-20 肽組合物

Country Status (11)

Country Link
US (3) US10196425B2 (zh)
EP (2) EP3450449A3 (zh)
JP (3) JP6622690B2 (zh)
CN (3) CN105492456A (zh)
AU (5) AU2014227712B2 (zh)
CA (1) CA2906694A1 (zh)
ES (1) ES2693761T3 (zh)
HK (1) HK1220697A1 (zh)
RU (2) RU2020120797A (zh)
TR (1) TR201815173T4 (zh)
WO (1) WO2014144260A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3539551T3 (pl) 2011-12-29 2022-02-21 Rhythm Pharmaceuticals, Inc. Sposób leczenia zaburzeń związanych z receptorem melanokortyny 4 u heterozygotycznych nosicieli
BR112015023409B1 (pt) 2013-03-15 2023-11-28 Rhythm Metabolic, Inc. Complexo iônico, composição farmacêutica compreendendo o referido complexo, seu uso e métodos de produção do referido complexo
EP3450449A3 (en) 2013-03-15 2019-06-12 Rhythm Pharmaceuticals, Inc. Peptide compositions
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
CA3000670A1 (en) * 2015-09-30 2017-04-06 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor pathway-associated disorders
US11591367B2 (en) * 2016-10-04 2023-02-28 Dsm Ip Assets B.V. Melanocortin-1-receptor agonists
MA49883A (fr) * 2017-03-15 2021-04-21 Novo Nordisk As Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
WO2019195756A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
WO2020053414A1 (en) * 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
CN113332416B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用
CN113209270B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备防治急性肝衰竭药物中的应用
CN116789802A (zh) * 2023-06-25 2023-09-22 湖北省农业科学院畜牧兽医研究所 一种山羊mc4r增强型突变体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3851002T2 (de) * 1987-05-22 1995-02-02 University Patents, Inc., Westport, Conn. Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung.
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
GB9827500D0 (en) * 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
AU2001284026B2 (en) * 2000-08-30 2007-03-01 F. Hoffmann-La Roche Ag Cyclic peptides having melanocortin-4 receptor agonist activity
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
IL159797A0 (en) 2001-07-11 2004-06-20 Palatin Technologies Inc Linear and cyclic melanocortin receptor-specific peptides
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
JP2006527772A (ja) * 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン３受容体（ｍｃ３ｒ）作用薬ペプチドの用途
AU2004251616A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(MC4) agonists and their uses
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US8343031B2 (en) * 2004-03-23 2013-01-01 Michael Gertner Obesity treatment systems
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
EP2286825B1 (en) 2005-07-08 2016-09-28 Ipsen Pharma Melanocortin receptor ligands
WO2007008684A2 (en) 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Ligands of melanocortin receptors
TWI364290B (en) 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
EP2167112A4 (en) 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
CA2952095C (en) 2007-11-05 2020-02-18 Ipsen Pharma S.A.S. Use of melanocortins to treat insulin sensitivity
US20090305960A1 (en) * 2008-06-09 2009-12-10 Palatin Technologies, Inc Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440227B1 (en) 2009-06-08 2017-10-18 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
CN102548399A (zh) * 2009-08-05 2012-07-04 益普生制药股份有限公司 黑皮质素治疗血脂异常的用途
EP2501225B1 (en) 2009-11-16 2017-11-01 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
US20120226018A1 (en) 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
WO2012172433A2 (en) 2011-06-14 2012-12-20 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as active ingredient
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
EP3450449A3 (en) * 2013-03-15 2019-06-12 Rhythm Pharmaceuticals, Inc. Peptide compositions
BR112015023409B1 (pt) * 2013-03-15 2023-11-28 Rhythm Metabolic, Inc. Complexo iônico, composição farmacêutica compreendendo o referido complexo, seu uso e métodos de produção do referido complexo

Also Published As

Publication number Publication date
RU2725150C2 (ru) 2020-06-30
AU2024200528A1 (en) 2024-02-15
EP3450449A3 (en) 2019-06-12
ES2693761T3 (es) 2018-12-13
AU2014227712A1 (en) 2015-10-01
RU2020120797A (ru) 2020-07-02
AU2020203353A1 (en) 2020-06-11
TR201815173T4 (tr) 2018-11-21
JP2016516719A (ja) 2016-06-09
US20210040155A1 (en) 2021-02-11
JP2019172693A (ja) 2019-10-10
AU2018256493A1 (en) 2018-11-22
AU2021269411A1 (en) 2021-12-16
EP2970388A1 (en) 2016-01-20
JP6622690B2 (ja) 2019-12-18
CA2906694A1 (en) 2014-09-18
WO2014144260A1 (en) 2014-09-18
RU2015145593A (ru) 2017-04-24
US10196425B2 (en) 2019-02-05
CN118240012A (zh) 2024-06-25
CN118271400A (zh) 2024-07-02
AU2014227712B2 (en) 2018-08-02
EP3450449A2 (en) 2019-03-06
US10858399B2 (en) 2020-12-08
JP7046871B2 (ja) 2022-04-04
EP2970388B1 (en) 2018-07-25
CN105492456A (zh) 2016-04-13
US20190092815A1 (en) 2019-03-28
JP2022084844A (ja) 2022-06-07
US20160017001A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
HK1216757A1 (zh) 肽化合物
ZA201505966B (en) Peptides and compositions
SG11201602596UA (en) Stabilized efinaconazole compositions
GB201304662D0 (en) Compositions
EP2889350A4 (en) ADHESIVE COMPOSITION
HK1220697A1 (zh) 肽組合物
GB201303771D0 (en) Nanoparticles peptide compositions
GB201313615D0 (en) Compositions
PT3061771T (pt) Novo péptido unido a quatro epitopos ctl
HK1216715A1 (zh) 基於血紅蛋白衍生肽的新型藥物組合物
HK1211596A1 (en) Peptide
ZA201505650B (en) New compositions
GB201316463D0 (en) Novel compositions
HK1211595A1 (en) Peptide
HK1198769A1 (zh) 新型肽
IL244956B (en) New peptide compositions
GB201320962D0 (en) Compositions
GB201303787D0 (en) Nanoparticle peptide compositions
GB201320959D0 (en) Compositions
GB201312224D0 (en) Compositions
GB201304927D0 (en) Compositions
GB201316464D0 (en) Novel compositions
GB201315598D0 (en) Novel compositions